Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Scientists at Dana-Farber Cancer Institute, who led the research, will report these findings at the annual meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 1, 2015.
https://www.healthcanal.com/cancers/63521-new-drug-combination-boosts-survival-in-advanced-stomach-and-esophageal.html
New drug combination boosts survival in advanced stomach and esophageal